Nano Holdings, Inc.
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/02/11 | ¥-3.79 | ¥-10.97 | -189.5% |
| 2015/08/11 | ¥-6.90 | ¥-7.20 | -4.4% |
| 2015/05/13 | ¥-9.27 | ¥-6.03 | +35.0% |
| 2015/02/12 | ¥-10.80 | ¥4.67 | +143.2% |
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥202M | ¥136M | ¥109M | ¥174M |
| Gross Profit | ¥160M | ¥111M | ¥78M | ¥153M |
| Operating Income | -¥1,246M | -¥864M | -¥755M | -¥966M |
| Pretax Income | -¥1,246M | -¥864M | -¥833M | -¥918M |
| Net Income | -¥1,311M | -¥780M | -¥835M | -¥944M |
| EPS | -¥18.70 | -¥11.10 | -¥11.85 | -¥12.90 |
| Operating Margin | -616.26% | -637.91% | -696.07% | -553.58% |
| Balance Sheet | ||||
| Total Assets | ¥5,784M | ¥5,071M | ¥3,997M | ¥5,906M |
| Total Equity | ¥4,253M | ¥3,421M | ¥2,740M | ¥3,565M |
| Total Liabilities | ¥1,531M | ¥1,650M | ¥1,257M | ¥2,341M |
| Cash | ¥2,812M | ¥2,078M | ¥1,707M | ¥4,910M |
| Interest-bearing Debt | ¥1,109M | ¥1,109M | ¥540M | ¥1,600M |
| Equity Ratio | 73.53% | 67.47% | 68.55% | 60.36% |
| D/E Ratio | 0.26 | 0.32 | 0.20 | 0.45 |
| Cash Flow | ||||
| Operating CF | -¥1,087M | -¥585M | -¥402M | -¥817M |
| Investing CF | ¥1,208M | ¥793M | ¥588M | ¥2,262M |
| Financing CF | - | ¥4M | -¥569M | ¥2,222M |
| Free CF | -¥1,087M | -¥585M | -¥402M | -¥817M |
| Efficiency | ||||
| ROE | -30.82% | -22.80% | -30.49% | -26.47% |
| ROA | -22.66% | -15.38% | -20.90% | -15.98% |
Latest IR Information
-
Notice Regarding Issuance of New Shares as Restricted Stock Compensation
Nano Holdings, Inc. will introduce a restricted stock compensation plan for employees and external collaborators and issue a total of 130,000 shares. Allottees are 2 employees (80,000 shares) and 1 external collaborator (50,000 shares). The issue price is 98 yen...
Read more -
Notice Regarding Monthly Exercise Status of Series 22 Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Published the monthly exercise status for Series 22 stock acquisition rights (with exercise price adjustment clause) for September 2026. Number of shares granted: 210,000 shares; number of exercised rights: 2,100; exercise ratio to total issued shares: 0.57%; unexercised at month-end:...
Read more -
Notice Regarding Issuance of New Shares through Third-Party Allotment
To secure funding for new life sciences-related projects, 3,139,700 shares of Cyntec Co., Ltd., a 100% subsidiary of OEP, are to be issued through a third-party allotment. The fundraising amount is approximately 310,830,000 yen, the paid-in price is 99 yen...
Read more -
Notice on the Monthly Exercise Status of Stock Acquisition Rights for 22nd Issue (Exercise Price Adjustment Clause)
Public disclosure of the August monthly exercise status for stock acquisition rights (with exercise price adjustment clause). Granted shares: 1,318,000 shares; exercised rights: 13,180 units, representing 0.35% of the issued total. Unexercised at the end of the previous month: 265,650...
Read more -
Notification on Monthly Exercise Status of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Provisions)
In the month, 260,000 shares of stock acquisition rights were issued, 2,600 rights were exercised (0.70%), and unexercised rights decreased from 268,250 to 265,650 shares. Overall exercise ratio 0.36%, details of the prior month’s figures disclosed. The indicated month lists...
Read more
Latest News (5 items)
Company Information
About
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.
